PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

B-500, Tower B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi -110029

Minutes of Pre-bid Meeting dated 08/10/2026

Section I: Top Sheet

File No:	PMBI/07/49/PROC/2026	**Date:**	08/10/2026
Description	e-Tender: PMBI/AYURVEDIC/RC-238/2026 Dated: 29.09.2026 for the supply of 9 nos. of Ayurvedic drug/items to Pharmaceuticals & Medical Devices Bureau of India (PMBI) for two years.	**Estimated Cost: -**	Rs.158.79 crores approx.
Tender Published In	CPP-portal & PMBI website	**Date of Publication**	01.10.2026
Bid Validity	150 days	**Bid Opening Date**	To be opened as per tender schedule.
Advertisement of the tender	The tender has been advertised through widely circulated News-papers viz. ***Dainik Jagran (Dehradun City & Delhi City), Deccan Chronicle Chennai, Deccan Herald Bengaluru City, Hindustan Times (Delhi & Mumbai), Sakshi Hyderabad, Prajavani and The Times of India (Ahmedabad & Hyderabad).***		

Section II:

PMBI officials attended the meeting:

Sr. No.	Name	Designation	Tender Committee (TC)
1	N.J.Sujatha	Deputy Chief Executive Officer	Chairperson/ Member
2	Ravikant Tiwari	General Manager (Finance & Accounts)	Member
3	Sanjay Kumar	External Expert	Member
4	Rinku Giri	Manager (Marketing & Sales)	Member
5	Prateek Mishra	Manager (Sale and Marketing and Procurement)	Member
6	Sanjay Lohani	Manager (Logistics & Supply chain)	Member
7	Sh. Jay Prakash Mishra	Deputy General Manager (Procurement)	Procurement Department Head
8	Sh. Rishabh Nagar	Deputy Manager (Procurement)	To present tender to Tender Committee
9	Sh. Prasant Kumar Thakur	Assistant Manager (Procurement)	To present tender to Tender Committee
10	Sh. Gaurav Kaushik	Junior Officer (Procurement)	Attendee

Section III: Deliberation on Salient Features of the Tender:

At the onset of the meeting, the representatives of the prospective bidders have been welcomed and they have been briefed about all the changes made in the instant tender over the earlier one. The inclusion of all new clauses was deliberated upon during the meeting. The representatives have been informed to read the tender very carefully outlining all major changes specially those under clause no. 3, 4, 14, 16, 18, 19, 20, 21, 22, 23, 26 and 27 including Annexure II, Annexure VII, VIII, XII and XIII respectively. Representatives have also been advised to adhere to formats in the tenders as applicable.

Further, Annexure VIII has been expounded by DGM (Procurement) emphasizing on the modifications in packaging standards. While answering a question raised by one of the participant manufacturers regarding price bid quotation (i.e., rate per tablet/ capsule), it has been elucidated that bidders shall quote rates strictly for the unit size as specified in Annexures XII and XIII and the BOQ only.

Section IV: Queries of the intending bidders discussed during the pre-bid meeting

Pre-bid meeting against the subject tender was scheduled on 07/10/2026 from 11:00 hours onwards. The meeting was scheduled to be convened in physical mode at Conference Hall, PMBI as well as in hybrid mode where the link to join the meeting through video conference mode was provided to the intending bidders based on their request as per tender provisions.

2. PMBI has received queries from manufacturers through email prior to the pre-bid meeting whereas the below mentioned representatives have attended the pre-bid meeting through Hybrid mode and through video conference mode.

i. Centaur Bioceuticals
ii. Sanskar Ayush Medicare Pvt. Ltd.
iii. Unijules Life science Ltd
iv. Zeon Lifesciences limited

3. At the onset, the representatives of respective manufacturers were welcomed, and the DGM (Procurement) apprised the prospective bidders about the recently updated criteria of submission of Batch Manufacturing Record (BMRs) and BPR for each quoted drugs, stringent modifications in tender documents and the inspections of new as well as included manufacturers where the compliance of utmost quality standards for PMBI products was emphasized.

4. Later, the prospective bidders were requested to offer their views/ suggestions/ queries one by one regarding the terms & conditions and other details of the e-tender document followed by the other detailed discussion on the submitted queries.

5. Regarding terms and conditions/ detailed or packaging specifications, the representatives have offered their views/ suggestions/ queries and the same is discussed hereunder in the table:

S. No.	Manufacturer Name (M/s)	Query/ Suggestions of the representatives	PMBI Clarification
1.	Unijules Life science Ltd.	Representative of the manufacturer has requested to accept the provisional turnover for the financial years (2025-26) along with the turnover for the year 2023-24 & 2024-25.	The Representative of the Firm has been advised to refer amendment (if any) in this regard.
2.	Sanskar Ayush Medicare Pvt. Ltd.	The representative joined the meeting virtually and introduced their firm. The representative further requested that the Ayush Premium Mark be accepted as an alternative to the WHO-GMP certificate to promote healthy competition, ensure transparency, and facilitate the participation of all eligible intending bidders.	The Tender Committee has noted the query raised by the firm and requested to refer the amendment (if any) in this regard.

M/s Zeon Lifesciences Ltd. has also participated in the pre-bid meeting and mentioned that they have both the WHO-GMP certificate and **Ayush Premium Mark** and these may be allowed. Upon which the Tender Committee has informed the attendees to refer the amendment if any in this regard. Again, one of the bidders Asoj Soft Caps Pvt. Ltd., has requested to change dosage form of DC-2376 (Ashwagandha 250mg to Ashwagandha 300mg as Softgel Capsule through mail dated 07/10/2026.

It is further informed that the purity of Isabgol Husk against item code: DC-2917,2918 and 2919 will be updated into the specification through amendment.

The chair concluded the meeting with vote of thanks.

Sd/-
Chief Executive Officer,
Pharmaceuticals & Medical Devices Bureau of India